Livagen (20mg Vial) Dosage Protocol
Khavinson liver short-peptide bioregulator (KEDA) — research-only; not approved, benefits unproven.
Mix & measure Livagen · 20 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, KEDA), a Khavinson short-peptide bioregulator associated with the liver[1][5]. This educational page outlines a once-daily subcutaneous example with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine, with no standardized human dosing established and no completed human efficacy trials — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 20 mg vial → ~6.67 mg/mL (6,667 mcg/mL).
500–2,000 mcg once daily, titrated upward gradually across a 12-week example course.
At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg; 500 mcg ≈ 7.5 units and 2,000 mcg = 30 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).
Example daily range: 500–2,000 mcg once daily, raised gradually over a 12-week course. No standardized human dosing has been established — this is an educational example only.
Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe. Divide the target dose in mcg by 66.7 to get the number of units.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day over a 12-week example course, titrating up gradually. To convert any dose, divide mcg by 66.7 to get U-100 units[3][4]. These figures are an educational example only — no standardized human dosing has been established for Livagen.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution is deliberately large so each dose reads at 30 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume a 12-week example course of once-daily injections with gradual titration.
A 20 mg vial covers roughly 10 days at the example schedule, so plan about one vial per ~10 days.
- Full 12-week course: ~6–7 vials
- Total peptide used: ~126 mg
- Average: ~10.5 mg per week
- Per injection: 1 syringe
- 12 weeks (once daily): ~84 syringes
Use ~3.0 mL per 20 mg vial for reconstitution.
- 12 weeks (~7 vials): ~21 mL → 3 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 12 weeks (once daily): ~168 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily example regimen described on this page.
- ▪Context: Livagen is studied as an epigenetic liver-associated bioregulator (chromatin decondensation) — a preclinical / in-vitro hypothesis, not established in humans[5][6].
- ▪Schedule: Once-daily subcutaneous injections over a 12-week example course.
- ▪Example Dose Range: 500–2,000 mcg per day with gradual titration; no standardized human dosing established.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 20 mg vial gives ~6.67 mg/mL for accurate unit measurements.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
An illustrative daily titration approach; no standardized human dosing is established for Livagen.
- ▪Start: Begin at 500 mcg once daily (weeks 1–2).
- ▪Titrate: Step up roughly every two weeks — 1,000 mcg (weeks 3–4), then 1,500 mcg (weeks 5–6).
- ▪Target: Reach about 2,000 mcg daily by weeks 7–12.
- ▪Cycle Length: A 12-week example course.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Livagen is not FDA- or EMA-approved for human use. It is not specifically named by WADA, but as a peptide bioregulator it could be scrutinised under gene/cellular-doping (M3) or the S0 catch-all — treat its competitive-sport status as high-risk / unclear[10].
How This Works
Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA)[1][2]. It belongs to the class of Khavinson short-peptide bioregulators and is the peptide most often associated with the liver.
Its proposed mechanism is epigenetic: in vitro the peptide is reported to bind condensed DNA and promote chromatin decondensation, which is hypothesised to de-repress silenced genes in the lymphocytes of elderly subjects[5][6]. This is a preclinical / in-vitro hypothesis, not established clinical pharmacology.
The supporting evidence is overwhelmingly Khavinson-group animal and in-vitro work, much of it published in Russian-language journals with limited independent replication[11]. The single human signal is a small observation of chromatin activation in elderly subjects — not a clinical efficacy trial[12].
Important caveat: there are no completed human efficacy trials of Livagen. Liver-rejuvenation, anti-aging and “gene reactivation” claims rest on preclinical and in-vitro data and should be read as unproven hypotheses, not established benefits.
Livagen is not an approved medicine (no FDA or EMA approval). It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
General healthy habits, listed for completeness; they are not specific to Livagen and imply no proven benefit.
- ▪Nutrition: A balanced diet with adequate protein supports general health.
- ▪Activity & rest: Balance appropriate movement with adequate rest.
- ▪Sleep: Aim for 7–9 hours to support overall health.
- ▪Stress: Manage stress with evidence-based practices for general wellbeing.
Potential Benefits & Side Effects
What preclinical and in-vitro literature describe; human evidence is essentially absent and benefits are unproven.
Potential Benefits
- ▪Chromatin activation (in-vitro): The peptide is reported to decondense chromatin and de-repress silenced genes in elderly lymphocytes — an unproven mechanistic hypothesis, not a clinical benefit[5][6].
- ▪Liver association (preclinical): Khavinson-group animal work links the KEDA peptide family to liver-related gene expression — mostly Russian-language studies with limited independent replication[11].
- ▪Anti-aging hypothesis (preclinical): Proposed “gene reactivation” / rejuvenation effects are theoretical and have not been demonstrated in controlled human trials.
- ▪Note on humans: These are not established in humans. The only human signal is a small chromatin-activation observation in elderly subjects — not a clinical efficacy trial[13].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport restriction: Livagen is not specifically named by WADA, but its competitive-sport status is unclear and potentially high-risk (possible M3/S0 scrutiny).
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides. Livagen may not be listed individually — check the supplier’s current catalog.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Khavinson, Biogerontology (PubMed)Peptides and ageing: short-peptide bioregulators of the Khavinson group, including the tetrapeptide Livagen (KEDA).
- 2
Khavinson et al., Bull. Exp. Biol. Med. (PubMed)Peptide Livagen (Lys-Glu-Asp-Ala): sequence and in-vitro effects on chromatin in cultured lymphocytes.
- 3
WADA Prohibited List — M3 & S0Gene/cellular doping (M3) and non-approved substances (S0): categories under which peptide bioregulators could be scrutinised.
- 4
Anisimov & Khavinson, review (PubMed)Peptide bioregulation of ageing: overview of short peptides; much of the primary work is Russian-language with limited independent replication.
- 5
Khavinson et al., chromatin study (PubMed)Livagen reported to decondense chromatin and de-repress silenced genes in lymphocytes of elderly subjects (in-vitro / small human observation).
- 6
Khavinson, epigenetic peptides (PubMed)Proposed epigenetic mechanism of short peptides: binding to DNA and modulation of gene expression (preclinical / in-vitro).
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
WADA Prohibited ListWADA Prohibited List: Livagen is not specifically named; status under M3 (gene/cellular doping) or S0 is unclear and treated as high-risk.
- 11
Bull. Exp. Biol. Med. (PubMed)Khavinson-group animal studies on liver-associated short peptides; predominantly Russian-language with limited independent replication.
- 12
Gerontology / chromatin activation (PubMed)Small observation of chromatin activation in elderly subjects exposed to the peptide — not a clinical efficacy trial.
- 13
ClinicalTrials.govTrial registry search: no completed human efficacy trials of Livagen (KEDA tetrapeptide).
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesResearch-peptide supplier — purity specifications and certificates of analysis (Livagen may not be listed individually).
How to reconstitute Livagen
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the Livagen vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
Livagen — frequently asked questions
How do I reconstitute a 20 mg vial of Livagen?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Livagen?
There is no single correct amount — more water simply spreads the same 20 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Livagen after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 20 mg vial of Livagen provide?
Divide the vial strength of 20 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Livagen approved for human use?
No. Livagen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.